Expression Profile of Cancer-Related miRNAs in HeLa Cervix Carcinoma Cells
Hussein Sabit1*, Mariam Zakaria2, Shimaa Abdel-Ghany2, Osama AM Said2, Manar Al-Abdullah3, Emre Cevik1, Amany Al-qosaibi4, Huseyin Tombuloglu1, Fatma Almulhim5 and Mokhtar El-Zawahry2,6
1Department of Genetics, Institute for Research and Medical Consultations, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia
2College of Biotechnology, MISR University for Science and Technology, Giza, Egypt
3Department of Physiotherapy, College of Medical Applied Science, Imam
Abdulrahman Bin Faisal University, Dammam, Saudi Arabia
4Department of Biology, College of Science, Imam Abdulrahman Bin Faisal
University, Dammam, Saudi Arabia
5Department of Radiology, College of Medicine, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia
6Research and Development Center, MISR University for Science and Technology, Giza, Egypt
*Corresponding Author: Hussein Sabit, Department of Genetics, Institute for
Research and Medical Consultations, Imam Abdulrahman Bin Faisal University,
Dammam, Saudi Arabia.
June 16, 2022; Published: July 12, 2022
Background: Cervical cancer (CC) is the second leading common cancer among women globally. The disease begins with abnormal changes in the cervical that is generally associated with infection with human papillomavirus (HPV). Studies indicated the crucial role of miRNAs in CC tumorigenesis, progression and metastasis. More than 40 miRNAs have been reported signifying their role in the regulation of CC.
Material and Methods: In the present study, the expression profiles of 24 miRNAs were measured using PCR array for tumor suppressor genes.
Results: We have reported 9 upregulated miRNA (hsa-miR-31-5p, hsa-miR-23b-3p, hsa-miR-30d-5p, hsa-miR-206, hsa-miR-20b-5p, hsa-miR-30c-4p, and hsa-miR-145-5p) and 15 downregulated. Using miRNet online prediction tool (link provided in the M and M section), genes, diseases, lncRNA, and small molecules were predicted for the upregulated group only. Data obtained indicated that 8 of the upregulated miRNAs in HeLa cervical cancer cells targets 2429 genes, two of them targets 20 different diseases, three of them target 31 small molecules, and eight of them targets 253 lncRNAs.
Conclusion: The present study revealed that hsa-miR-20b-5p could be used as a potential biomarker because of its high expression profile in CC cells.
Keywords: miRNA; Cervical Cancer; Hela; Profiling
- Souho T., et al. “Cancer hallmarks and malignancy features: Gateway for improved targeted drug delivery”. Biotechnology Advances (2018).
- Wang H., et al. “Cancer Radiosensitizers”. Trends in Pharmacological Sciences1 (2018): 24-48.
- Siegel RL., et al. “Cancer Statistics, 2017”. CA: A Cancer Journal for Clinicians1 (2017): 7-30.
- Siegel RL., et al. “Cancer statistics, 2018”. CA: A Cancer Journal for Clinicians1 (2018): 7-30.
- Minion LE and Tewari KS. “Cervical cancer - State of the science: From angiogenesis blockade to checkpoint inhibition”. Gynecologic Oncology3 (2018): 609-621.
- Crafton SM and Salani R. “Beyond Chemotherapy: An Overview and Review of Targeted Therapy in Cervical Cancer”. Clinical Therapeutics3 (2016): 449-458.
- Vu M., et al. “Cervical cancer worldwide”. Current Problems in Cancer (2018).
- Li MY and Hu XX. “Meta-analysis of microRNA expression profiling studies in human cervical cancer”. Medical Oncology6 (2015).
- Yost S and Hoekstra A. “Cervical cancer in women over 65: An analysis of screening”. Gynecologic Oncology Reports 25 (2015): 48-51.
- Matsuo K., et al. “Incidences and risk factors of metachronous vulvar, vaginal, and anal cancers after cervical cancer diagnosis”. Gynecologic Oncology3 (2018): 501-508.
- Fayz s., et al. “Cervical cancer diagnosis using random forest classifier with smote and feature reduction techniques”. Ieee Access (2018): 1-1.
- Davis M., et al. “The impact of health insurance status on the stage of cervical cancer diagnosis at a tertiary care center in Massachusetts”. Gynecologic Oncology1 (2018): 67-72.
- Sun G., et al. “Cervical Cancer Diagnosis based on Random Forest”. International Journal of Performability Engineering4 (2017): 446.
- Burki TK. “Cervical cancer diagnosis and the US Affordable Care Act”. The Lancet Oncology1 (2016): e10-e10.
- Laengsri V., et al. “Cervical Cancer Markers: Epigenetics and microRNAs”. Laboratory Medicine2 (2018): 97-111.
- Liu B., et al. “Seven protective miRNA signatures for prognosis of cervical cancer”. Oncotarget 35 (2016): 56690.
- Pedroza-Torres A., et al. “MicroRNAs in cervical cancer: evidences for a miRNA profile deregulated by HPV and its impact on radio-resistance”. Molecules (Basel, Switzerland) 5 (2014): 6263-6281.
- Tang T., et al. “MicroRNA-182 plays an onco-miRNA role in cervical cancer”. Gynecologic Oncology1 (2012): 199-208.
- Sharma G., et al. “A Comprehensive Review of Dysregulated miRNAs Involved in Cervical Cancer”. Current Genomics 4 (2014): 310-323.
- Azizmohammadi S., et al. “Molecular identification of miR-145 and miR-9 expression level as prognostic biomarkers for early-stage cervical cancer detection”. QJM 1 (2017): 11-15.
- Li C., et al. “Serum miR-486-5p as a diagnostic marker in cervical cancer: With investigation of potential mechanisms”. BMC Cancer 1 (2018).
- Baretti M and Azad NS. “The role of epigenetic therapies in colorectal cancer”. Current Problems in Cancer (2018).
- Sessa R., et al. “The miR-126 regulates Angiopoietin-1 signaling and vessel maturation by targeting p85β”. Biochimica et Biophysica Acta - Molecular Cell Research 10 (2012): 1925-1935.
- Sonntag KC., et al. “Converging miRNA functions in diverse brain disorders: A case for miR-124 and miR-126”. Experimental Neurology2 (2012): 427-435.
- Xu X-M., et al. “MicroRNA-19a and -19b regulate cervical carcinoma cell proliferation and invasion by targeting CUL5”. Cancer Letters2 (2012): 148-158.
- Fan YN., et al. “miRNet - dissecting miRNA-target interactions and functional associations through network-based visual analysis”. Nucleic Acids ResearchW1 (2016): W135-W141.
- Balmayor ER., et al. “2.26 MicroRNA as Biomaterial”. In: Ducheyne P, editor. Comprehensive Biomaterials II. Oxford: Elsevier (2017): 558-570.
- Velmurugan G., et al. “5 - Functional Genomics of MicroRNAs”. In: Gunasekaran P, Noronha S, Pandey A. Current Developments in Biotechnology and Bioengineering: Elsevier (2017): 103-121.
- Dobson JR., et al. “hsa-mir-30c promotes the invasive phenotype of metastatic breast cancer cells by targeting NOV/CCN3”. Cancer Cell International1 (2014): 73.
- Bin L., et al. “Down-regulation of miRNA-30c predicts poor prognosis in Colorectal Cancer patients”. Revista Romana de Medicina de Laborator4 (2016): 369-375.
- Liu D., et al. “Downregulation of miRNA-30c and miR-203a is associated with hepatitis C virus core protein-induced epithelial-mesenchymal transition in normal hepatocytes and hepatocellular carcinoma cells”. Biochemical and Biophysical Research Communications4 (2015): 1215-1221.
- Jia W., et al. “MicroRNA-30c-2 expressed in ovarian cancer cells suppresses growth factor-induced cellular proliferation and downregulates the oncogene BCL9”. Molecular Cancer Research: MCR12 (2011): 1732-1745.
- Yanokura M., et al. “MicroRNAS in endometrial cancer: recent advances and potential clinical applications”. EXCLI Journal 14 (2015): 190.
- Rodríguez-González FG., et al. “MicroRNA-30c expression level is an independent predictor of clinical benefit of endocrine therapy in advanced estrogen receptor positive breast cancer”. Breast Cancer Research and Treatment1 (2011): 43-51.
- Karsy M., et al. “Current Progress on Understanding MicroRNAs in Glioblastoma Multiforme”. Genes and Cancer1 (2012): 3-15.
- Yoshino H., et al. “Aberrant expression of microRNAs in bladder cancer”. Nature Reviews Urology7 (2013): 396-404.
- He L., et al. “MicroRNA-181b expression in prostate cancer tissues and its influence on the biological behavior of the prostate cancer cell line PC-3”. Genetics and Molecular Research: GMR2 (2013): 1012-1021.
- Zhou Q., et al. “Smad2/3/4 Pathway Contributes to TGF-β-Induced MiRNA-181b Expression to Promote Gastric Cancer Metastasis by Targeting Timp3”. Cellular Physiology and Biochemistry 2 (2016): 453-466.
- Cai B., et al. “miRNA-181b increases the sensitivity of pancreatic ductal adenocarcinoma cells to gemcitabine in vitro and in nude mice by targeting BCL-2”. Oncology Reports5 (2013): 1769-1776.
- Li YX., et al. “MiR-30a-5p confers cisplatin resistance by regulating IGF1R expression in melanoma cells”. BMC Cancer 1 (2018): 1-10.
- Shu J., et al. “Dynamic and Modularized MicroRNA Regulation and Its Implication in Human Cancers”. Scientific Reports1 (2017): 13356-17.
- Campos-Viguri GE., et al. “miR-23b as a potential tumor suppressor and its regulation by DNA methylation in cervical cancer”. Infectious Agents and Cancer1 (2015): 42.
- An Y., et al. “MiR-23b-3p regulates the chemoresistance of gastric cancer cells by targeting ATG12 and HMGB2”. Cell Death and Disease 5 (2015): e1766-e1766.
- Kurogi R., et al. “Inhibition of glioblastoma cell invasion by hsa-miR-145-5p and hsa-miR-31-5p co-overexpression in human mesenchymal stem cells”. Journal of Neurosurgery (2018): 1-12.
- Mataki H., et al. “Dual-strand tumor-suppressor microRNA-145 (miR-145-5p and miR-145-3p) coordinately targeted MTDH in lung squamous cell carcinoma”. Oncotarget44 (2016): 72084.
- Lin Y., et al. “A Plasma Long Noncoding RNA Signature for Early Detection of Lung Cancer”. Translational Oncology5 (2018): 1225-1231.
- Li JW., et al. “The four-transmembrane protein MAL2 and tumor protein D52 (TPD52) are highly expressed in colorectal cancer and correlated with poor prognosis”. PloS one5 (2017): e0178515.
- Tian T., et al. “SNHG1 promotes cell proliferation by acting as a sponge of miR-145 in colorectal cancer”. Oncotarget 2 (2018): 2128-2139.
- Yoshimoto R., et al. “MALAT1 long non-coding RNA in cancer”. BBA - Gene Regulatory Mechanisms 1 (2016): 192-199.
- Xi YH., et al. “Long non-coding HCG18 promotes intervertebral disc degeneration by sponging miR-146a-5p and regulating TRAF6 expression”. Scientific Reports1 (2017): 13234-13239.